Transcutaneous vaccination with virus-like particles.

[1]  K. Beagley,et al.  Induction of anti-chlamydial mucosal immunity by transcutaneous immunization is enhanced by topical application of GM-CSF. , 2005, Current molecular medicine.

[2]  J. Wilschut,et al.  The virosome concept for influenza vaccines. , 2005, Vaccine.

[3]  D. Sack,et al.  Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis , 2005, The Lancet.

[4]  T. Ramqvist,et al.  Murine polyomavirus virus-like particles (VLPs) as vectors for gene and immune therapy and vaccines against viral infections and cancer. , 2005, Anticancer research.

[5]  C. Wheeler,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized, controlled trial , 2005 .

[6]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[7]  G. Buchan,et al.  Bystander Help within a Polyepitope DNA Vaccine Improves Immune Responses to Influenza Antigens , 2004, Scandinavian journal of immunology.

[8]  H. Ploegh,et al.  Translating cell biology in vitro to immunity in vivo , 2004, Nature.

[9]  S. Muller,et al.  Modulation of immune responses with transcutaneously deliverable adjuvants. , 2004, Vaccine.

[10]  G. Jennings,et al.  Virus‐Like Particles: Combining Innate and Adaptive Immunity for Effective Vaccination , 2004 .

[11]  J. Berzofsky,et al.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. , 2004, The Journal of clinical investigation.

[12]  A. Rothfuchs,et al.  Macrophages, CD4+ or CD8+ Cells Are Each Sufficient for Protection against Chlamydia pneumoniae Infection through their Ability to Secrete IFN-γ1 , 2004, The Journal of Immunology.

[13]  P. Hansbro,et al.  Transcutaneous Immunization with Combined Cholera Toxin and CpG Adjuvant Protects against Chlamydia muridarum Genital Tract Infection , 2004, Infection and Immunity.

[14]  K. Schwarz,et al.  Nonmethylated CG Motifs Packaged into Virus-Like Particles Induce Protective Cytotoxic T Cell Responses in the Absence of Systemic Side Effects , 2004, The Journal of Immunology.

[15]  R. Gie,et al.  Danish bacille Calmette-Guérin vaccine-induced disease in human immunodeficiency virus-infected children. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  K. Kelly.  CELLULAR IMMUNITY AND CHLAMYDIA GENITAL INFECTION: INDUCTION, RECRUITMENT, AND EFFECTOR MECHANISMS , 2003, International reviews of immunology.

[17]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[18]  R. Salmond,et al.  Immune modulation by the cholera-like enterotoxins , 2002, Expert Reviews in Molecular Medicine.

[19]  A. Krieg,et al.  Enhancing vaccines with immune stimulatory CpG DNA. , 2001, Current opinion in molecular therapeutics.

[20]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[21]  P. Coursaget,et al.  Gene Transfer Using Recombinant Rabbit Hemorrhagic Disease Virus Capsids with Genetically Modified DNA Encapsidation Capacity by Addition of Packaging Sequences from the L1 or L2 Protein of Human Papillomavirus Type 16 , 2000, Journal of Virology.

[22]  P. Timms,et al.  Chlamydia trachomatis infection: incidence, health costs and prospects for vaccine development. , 2000, Journal of reproductive immunology.

[23]  Y. Tokura,et al.  Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  T. Jakob,et al.  Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. , 1998, Journal of immunology.

[25]  M. Starnbach,et al.  Protective cytotoxic T lymphocytes are induced during murine infection with Chlamydia trachomatis. , 1994, Journal of immunology.

[26]  D. Rasschaert,et al.  Recombinant rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection , 1994, Journal of virology.

[27]  L. Babiuk,et al.  Novel vaccine strategies. , 2002, Advances in virus research.

[28]  D. Graham,et al.  Virus-like particle vaccines for mucosal immunization. , 1997, Advances in experimental medicine and biology.